With about 20M shares, I doubt John Commissioning is concerned about acquiring more at the current share price. Based on what I've read about him, he's more focused on the science and discovery of new Neurotrophic Factors. Gerald commented recently that John was continuing his PhenoGuard work at the Janssen Labs QB3 incubator site after the corporate offices were moved to another location.

http://www.sec.gov/cgi-bin/own-disp?action=ge...0001619589

Trying to connect John's lack of purchases to a lack of faith in the company is grasping at straws.